Details:

Personal Author:
Dooling, Kathleen ; Gargano, Julia W. ; Moulia, Danielle ; Wallace, Megan ; Rosenblum, Hannah G. ; ... More +
Dooling, Kathleen ; Gargano, Julia W. ; Moulia, Danielle ; Wallace, Megan ; Rosenblum, Hannah G. ; Blain, Amy E. ; Hadler, Stephen C. ; Plumb, Ian D. ; Moline, Heidi ; Gerstein, Jack ; Collins, Jennifer P. ; Godfrey, Monica ; Campos-Outcalt, Doug ; Morgan, Rebecca L. ; Brooks, Oliver ; Talbot, H. Keipp ; Lee, Grace M. ; Daley, Matthew F. ; Oliver, Sara E. Less -
Corporate Authors:
United States. Advisory Committee on Immunization Practices. ; CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. ; University of Arizona. College of Medicine. ; McMaster University. Faculty of Health Sciences. Department of Health Research Methods, Evidence, and Impact. ; ... More +
United States. Advisory Committee on Immunization Practices. ; CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. ; University of Arizona. College of Medicine. ; McMaster University. Faculty of Health Sciences. Department of Health Research Methods, Evidence, and Impact. ; Watts Healthcare Corporation. ; Vanderbilt University School of Medicine. ; Stanford University School of Medicine. ; Kaiser Permanente Colorado. Institute for Health Research. Less -
Description:
What is already known about this topic? On August 23, 2021, the Food and Drug Administration granted full approval of the Pfizer-BioNTech COVID-19 vaccine for persons aged ≥16 years.

What is added by this report? On August 30, 2021, after a systematic review of the data, the Advisory Committee on Immunization Practices revised its interim recommendation to a standard recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19.

What are the implications for public health practice? Continued use of the Pfizer-BioNTech COVID-19 vaccine, now fully approved by the FDA in persons aged ≥16 years, is recommended based on increased certainty that its benefits (prevention of asymptomatic infection, COVID-19, and associated hospitalization and death) outweigh vaccine-associated risks. Suggested citation for this article: Self WH, Tenforde Suggested citation for this article: Dooling K, Gargano JW, Moulia D, et al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021. MMWR Morb Mortal Wkly Rep. ePub: 21 September 2021.

mm7038e2.htm?s_cid=mm7038e2_w#contribAff

mm7038e2-H.pdf


Subjects:
[+]
Adolescent Adult Advisory Committees Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Drug Approval Immunization/standards Vaccination Viral Vaccines
Series:
MMWR. Morbidity and mortality weekly report ; v. 70, early release, September 21, 2021
Document Type:
Journal Article
Name as Subject:
Pfizer-BioNTech COVID-19 vaccine ; Pfizer-BioNTech COVID-19 vaccine
Pfizer-BioNTech COVID-19 vaccine ; Pfizer-BioNTech COVID-19 vaccine Less -
Place as Subject:
Alabama ; Arizona ; Colorado ; Indiana ; Los Angeles, CA ; ... More +
Alabama ; Arizona ; Colorado ; Indiana ; Los Angeles, CA ; Louisiana ; Maryland ; Minnesota ; New Mexico ; New York City, NY ; North Carolina ; Seattle, WA ; Utah Less -
Location:
North America
Collection(s):
Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:2928496890a5d73be44df6c74f7b7f28a6f12174fda3c619e4669b22e1b05558
Download URL:
https://stacks.cdc.gov/view/cdc/109943/cdc_109943_DS1.pdf
File Type:

Supporting Files

• mm7038e2.htm

  htm

More +